What they were paid
Syndax Pharmaceuticals Director Compensation Table · the one fiscal year held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $60,000 | $366,250 | $0 | $0 | $426,250 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Syndax Pharmaceuticals Inc DEF 14A filed April 30, 2026, accession 0001193125-26-197859, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025Syndax Pharmaceuticals pays directors a $25,000 cash retainer and $366,250 in equity.
Committees
FY2025 · as the proxy prints themNominating/Governance · Science and Technology
The rest of the Syndax Pharmaceuticals board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Dennis G. Podlesak | Chair of the Board | $947,000 |
| Jennifer Jarrett | Independent Director | $433,750 |
| Keith A. Katkin | Independent Director | $511,250 |
| Martin H. Huber, M.D | Independent Director | $433,750 |
| Michael A. Metzger | Director | $0 |
| Pierre Legault | Independent Director | $503,750 |
The full Syndax Pharmaceuticals compensation record
free company briefThis page is one director within Syndax Pharmaceuticals's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat